Hassoun FK506, a promising new immunosuppressant, is currently under clinical investigation. Because dose-dependent toxicity is possible, blood concentrations of FK506 should be monitored. We improved the original ELISA of FK506 by shortening the incubationtime. With some modification of materials, results are obtained within 6 h instead of 2 days, with similar or even better precision. Internal and external quality-control programs showed that our results correlated satisfactorily both with values determined by the original method and the theoretical expected values. Either plasma (detection limit 0.1 g/L) or whole-blood (detection limit 1 .tg/L) samples can be used. The sensitivity of the method makes it particularly useful for accurate pharmacokinetic studies or measurement of low blood concentrations. Twenty-four drugs and nine biological variables showed no significant interference on the assay. Study of the concentration-and temperaturedependent distribution of FK506 shows that the drug is largely bound to erythrocytes (ratio of blood to plasma concentrations is ; as the erythrocytes become saturated, more of the drug is found in the plasma. Plasma concentrations may vary according to the blood temperature. We condude that whole blood should be used for FK506 monitoring, as it is for monitoringcyclosporine. 27% (5) and from 13%to23%(6). The purpose of the present study was to improve the precision and accuracy of the assay and decrease the incubation time. By reducing the assay time, we could provide a clinically useful result on the same day that blood is drawn. We assessed the performance 'of the modified assay, using both internal quality controls and an external international quality-control program. We investigated the effect of blood temperature on the distribution of FK506. In addition, we determined how the duration and temperature of the incubation affects the performance of the assay. We tested numerous drugs and biological conditions such as hyperlipidemia and hyperproteinemia to determine which would interfere in the assay. Finally, plasma concentrations of FK506 were correlated with whole-blood concentrations, and
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Preparation of Quality-Control Samples
Drug-free human plasma and whole blood were obtained from the blood bank to prepare control samples fortified with FK506 (0.5 and 1.5 jgfL in plasma; 10 and 30 p.gfL in whole blood). Aliquots of these samples were stored frozen until used to determine accuracy and precision.
Plate Preparation
Freshly prepared solution of polydonal anti-mouse antibody (200 L, 2.5 mgfL in PBS) is added to each well. The plate is covered with Parafilm and agitated on a plate rotator at 4#{176}C. The plates should be coated 24 h before the assay is performed. However, we found that coated and covered plates are stable up to 3 days at 4#{176}C. 
Plasma Sample Preparationand Solid-Phase Extraction
All standard, control, and patients' samples are analyzed in duplicate; 100 jL of plasma, either from the blood bank (for calibration samples) or from patients, is added to 1 mL of 0.1 mol/L HC1 with 10 L of standard solution (FK506 in methanol) or methanol blank. Calibration samples have final FK506 concentrations of 10, 5, 2.5, 1.25, 0.625, 0.312, and 0.156 gfL of plasma. We prepared C18 columns by washing them first with 2 mL of methanol and then with 2 mL of 0.67 mol/L aqueous acetic acid under reduced pressure. Next, 1 mL of the diluted and vortex-mixed plasma specimen is allowed to pass through the cartridge, which is subsequently washed again with 2 mL of 0.67 molIL acetic acid. FK506 is then eluted with 2 mL of methanol. The eluate is collected and evaporated to dryness. Recycling the C18 Bond-Elut columns is possible after adequate washing and preparation (3 mL of methanol and 2 mL of 0.67 mol/L acetic acid). The assay requires 5-6 h toperform,and the detection limit is 0.1 g/L in plasma and 1 agfL in whole blood. We shortenedthe incubationphase to 2 h at room temperature(around 20#{176}C, maintained by airconditioning) and compared the results obtained with thoseobtainedwith the originalincubation period(overnight at 4#{176}C). We found no statistical difference for patients' samples (Student's t-test, not significant; n = 24,slope1.05, and r = 0.976), provided both incubating plates were agitated ( Figure  3) . If samples are incubated for 2 h without agitation, a statistically significant decrease (± 10%) in the mea- The temperature of the blood specimen is an important factor, which must be controlled. Maintained at 37#{176}C before centrifugation, plasma specimens from transplant patients display FK506 concentrations twoto threefold higher than those of samples kept at 20#{176}C until centrifugation (n = 48, = 2.63 ± 1). Figure 4 shows (after 1 h of incubation of the blood sample at 37#{176}C) the FK506 residual fraction in plasma as a function of the time elapsed at room temperature before centrifugation. An equilibrium seems to be reached after 30 mm.
None of the drugs and dinical biochemistry variables tested ( Table 1) whole blood (n = 10) maintained at room temperature was evaluated by ELISA during five consecutive days. A slight and progressive decrease (10-30%) was observed at the end of this period, both in plasma and whole blood.
DiscussIon
The aim of this work was to modify the original assay for FK506 so that results would be available on the day of analysis and to improve, if possible, the accuracy and precision of the assay. or toxicity and the distribution of these metabolites in the blood require further elucidation. We describe similar FK506 distribution ratios (whole blood/plasma) and similar findings about the influence of temperature on FK506 plasma concentration measurements as were noted by other centers (6, 7, 10, 11). However, we did not observe any significant influence of the hematocrit on the FK506 distribution ratio as was reported elsewhere (11, 12). This contradiction is perhaps explained by the fact that the two groups cited above performed in vitro studies, using blood specimens fortifiedwith FK506 that sometimes had hematocrit ranges as large as 0.10-0.70, whereas our purpose was to investigate the influence of the hematocrit in clinical situations such as in the actual range of hematocrit found in liver transplant patients. We believe that whole-blood measurements will replace plasma determinations for FK5OG, just as they did for cyclosporine.
In the near future, Abbott Laboratories will introduce an automated whole-blood MEIA (microparticle enzyme iinmunoassay) to measure FK506 on the JMx analyzer (13). This attractive method should be able to provide results within 45 miii with a significant improvement in interassay and interlaboratory reproducibility. However, it has not yet been validated in clinical situations, and its sensitivity limit of 5 gfL of whole blood might be inadequate for low-dose therapy or for accurate pharrnacokinetics.
Therefore, in the meantime, the modified ELISA remains a method of choice for these applications.
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